Ermium Therapeutics Extends Its Initial €6,3 M Funding to €12,3 M to Further Advance Breakthrough Auto-Immune Disease Therapeutics
PARIS--(BUSINESS WIRE)--Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Health...